<!DOCTYPE html>
        <html lang="en">
        <head>
          <meta charset="UTF-8" />
          <meta name="viewport" content="width=device-width, initial-scale=1.0" />
          <title>MinMaxMuscle | Elamipretide (SS-31)</title>
          <meta name="description" content="Curated source summaries for Elamipretide (SS-31)." />
          <link rel="stylesheet" href="../assets/css/style.css" />
        </head>
        <body>
          <header>
            <div class="nav-container">
              <div class="logo">
                <img src="../assets/img/logo.png" alt="MinMaxMuscle Logo" />
                <span>MINMAXMUSCLE</span>
              </div>
              <nav class="desktop-nav">
                <a href="../index.html">Home</a>
                <a href="../training.html">Training</a>
                <a href="../nutrition.html">Nutrition</a>
                <a href="../peptides.html">Peptides</a>
                <a href="../coaching.html">Coaching</a>
                <a href="https://blog.minmaxmuscle.com">Blog</a>
                <a href="https://blog.minmaxmuscle.com/forum">Forums</a>
                <a href="../contact.html">Contact</a>
              </nav>
              <div class="hamburger" id="hamburger">
                <span></span>
                <span></span>
                <span></span>
              </div>
            </div>
            <div class="mobile-menu" id="mobileMenu">
              <a href="../index.html">Home</a>
              <a href="../training.html">Training</a>
              <a href="../nutrition.html">Nutrition</a>
              <a href="../peptides.html">Peptides</a>
              <a href="../coaching.html">Coaching</a>
              <a href="https://blog.minmaxmuscle.com">Blog</a>
              <a href="https://blog.minmaxmuscle.com/forum">Forums</a>
              <a href="../contact.html">Contact</a>
            </div>
          </header>
          <main>
            <section class="hero">
              <h1>Elamipretide (SS-31)</h1>
              <p>Automated source summaries for educational review. Verify claims with qualified professionals.</p>
            </section>
            <section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://en.wikipedia.org/wiki/Elamipretide" rel="noopener noreferrer" target="_blank">https://en.wikipedia.org/wiki/Elamipretide</a></p>
  <ul>
    <li>Main page</li><li>Contents</li><li>Current events</li><li>Random article</li><li>About Wikipedia</li><li>Contact us</li><li>Help</li><li>Learn to edit</li><li>Community portal</li><li>Recent changes</li><li>Upload file</li><li>Special pages</li><li>Donate</li><li>Create account</li><li>Log in</li><li># Contents</li><li>(Top)</li><li>1 Medical uses</li><li>2.1 Legal status</li><li>2.2 Names</li><li>3 References</li><li>4 Further reading</li><li>5 External links</li><li># Elamipretide</li><li>Русский</li><li>Article</li><li>Talk</li><li>Read</li><li>Edit</li><li>View history</li><li>What links here</li><li>Related changes</li><li>Permanent link</li><li>Page information</li><li>Cite this page</li><li>Get shortened URL</li><li>Download QR code</li><li>Download as PDF</li><li>Printable version</li><li>Wikimedia Commons</li><li>Wikidata item</li><li>US DailyMed : Elamipretide</li><li>None</li><li>US : ℞-only [ 1 ]</li><li>(2 S )-6-Amino-2-[[(2 S )-2-[[(2 R )-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]- N -[(2 S )-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide</li><li>736992-21-5</li><li>as HCl: 72244098-12-0</li><li>11764719</li><li>DB11981</li><li>9939410</li><li>87GWG91S09</li><li>as HCl: E40WZ3BK2D</li><li>D10925</li><li>as HCl: D11542</li><li>DTXSID50471988</li><li>Interactive image</li><li>CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(N)=O</li><li>InChI=1S/C32H49N9O5/c1-19-15-22(42)16-20(2)23(19)18-27(41-29(44)24(34)11-8-14-38-32(36)37)31(46)39-25(12-6-7-13-33)30(45)40-26(28(35)43)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-27,42H,6-8,11-14,17-18,33-34H2,1-2H3,(H2,35,43)(H,39,46)(H,40,45)(H,41,44)(H4,36,37,38)/t24-,25+,26+,27+/m1/s1</li><li>Key:SFVLTCAESLKEHH-WKAQUBQDSA-N</li><li>Elamipretide (development codes SS-31 , MTP-131 ), [ 2 ] sold under the brand name Forzinity , is a medication used for the treatment of Barth syndrome . [ 1 ] [ 3 ] Elamipretide is a mitochondrial cardiolipin binder. [ 1 ] It is used as the hydrochloride salt . [ 1 ] It is given by injection under the skin (subcutaneous). [ 1 ]</li><li>The most common side effects identified in clinical trials include mild-to-moderate injection site reactions. [ 4 ]</li><li>Elamipretide was approved for medical use in the United States in September 2025. [ 4 ]</li><li># Medical uses</li><li>Elamipretide is indicated to improve muscle strength in people with Barth syndrome weighing at least 30 kilograms (66 lb). [ 1 ]</li><li>Barth syndrome is a rare, serious and life-threatening disease of the mitochondria (the energy-producing parts of cells). [ 4 ] Barth syndrome primarily affects males, typically starts with severe heart failure in infancy, and causes premature death. [ 4 ] People who survive into adolescence and adulthood often have fatigue, poor stamina, and exercise intolerance. [ 4 ] The quality of life and daily functioning of people with Barth syndrome are significantly affected throughout their lives. [ 4 ]</li><li>Elamipretide has also been researched for numerous other indications including heart failure , macular degeneration , enhanced wound healing and hypertension , though it is currently only medically approved for use in the treatment of Barth syndrome. [ 5 ] [ 6 ] [ 7 ] [ 8 ] [ 9 ] [ 10 ] [ 11 ] [ 12 ] [ 13 ] [ 14 ] [ excessive citations ]</li><li># Society and culture</li><li># Legal status</li><li>Elamipretide was approved for medical use in the United States in September 2025. [ 4 ] The US Food and Drug Administration (FDA) granted the application for elamipretide priority review and rare pediatric disease designations. [ 4 ] The FDA granted accelerated approval of Forzinity to Stealth Biotherapeutics. [ 4 ]</li><li># Names</li><li>Elamipretide is the international nonproprietary name . [ 15 ]</li><li>Elamipretide is sold under the brand name Forzinity. [ 16 ]</li><li># References</li><li>^ a b c d e f https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf [ bare URL PDF ]</li><li>^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}} Szeto HH (2014). "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics" . British Journal of Pharmacology . 171 (8): 2029– 2050. doi : 10.1111/bph.12461 (inactive 18 November 2025). PMC 3976620 . PMID 24117165 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ Jacob N, Schecter D, Marshall M, Bansal N, Lamour J, Vernon H, et al. (2025). "Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report". Molecular Genetics and Metabolism . 146 ( 1– 2) 109220. doi : 10.1016/j.ymgme.2025.109220 (inactive 18 November 2025). PMID 40816230 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ a b c d e f g h i "FDA Grants Accelerated Approval to First Treatment for Barth Syndrome" . U.S. Food and Drug Administration (FDA) . 19 September 2025 . Retrieved 20 September 2025 . This article incorporates text from this source, which is in the public domain .</li><li>^ Steggall A, Mordi I, Lang C (2017). "Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure" . Diseases . 5 (2): 14. doi : 10.3390/diseases5020014 (inactive 18 November 2025). PMC 5547981 . PMID 28933367 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ Cano Sanchez M, Lancel S, Boulanger E, Neviere R (2018). "Targeting Oxidative Stress and Mitochondrial Dysfunction in the Treatment of Impaired Wound Healing: A Systematic Review" . Antioxidants . 7 (8): 98. doi : 10.3390/antiox7080098 (inactive 18 November 2025). PMC 6115926 . PMID 30042332 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ Eirin A, Lerman A, Lerman LO (2018). "Enhancing Mitochondrial Health to Treat Hypertension" . Current Hypertension Reports . 20 (10) 89. doi : 10.1007/s11906-018-0889-4 (inactive 18 November 2025). PMC 6524134 . PMID 30120623 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ Szeto HH (2019). "Stealth Peptides Target Cellular Powerhouses to Fight Rare and Common Age-Related Diseases". Protein & Peptide Letters . 25 (12): 1108– 1123. doi : 10.2174/0929866525666181101105209 (inactive 18 November 2025). PMID 30381054 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ Obi C, Smith AT, Hughes GJ, Adeboye AA (2022). "Targeting mitochondrial dysfunction with elamipretide". Heart Failure Reviews . 27 (5): 1925– 1932. doi : 10.1007/s10741-021-10199-2 (inactive 18 November 2025). PMID 35037146 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ Nhu NT, Xiao S, Liu Y, Kumar VB, Cui Z, Lee S (2022). "Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration" . Frontiers in Integrative Neuroscience . 15 747901. doi : 10.3389/fnint.2021.747901 (inactive 18 November 2025). PMC 8801496 . PMID 35111001 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ Tung C, Varzideh F, Farroni E, Mone P, Kansakar U, Jankauskas SS, et al. (2025). "Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential" . International Journal of Molecular Sciences . 26 (3): 944. doi : 10.3390/ijms26030944 (inactive 18 November 2025). PMC 11816484 . PMID 39940712 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ Sabbah HN, Alder NN, Sparagna GC, Bruce JE, Stauffer BL, Chao LH, et al. (2025). "Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects" . Biomedicine & Pharmacotherapy . 187 118056. doi : 10.1016/j.biopha.2025.118056 (inactive 18 November 2025). PMC 12164653 . PMID 40294492 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ Radovic M, Gartzke LP, Wink SE, Van Der Kleij JA, Politiek FA, Krenning G (2025). "Targeting the Electron Transport System for Enhanced Longevity" . Biomolecules . 15 (5): 614. doi : 10.3390/biom15050614 (inactive 18 November 2025). PMC 12109555 . PMID 40427507 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ Patel PS, Pabla NS, Bajwa A (2025). "Therapeutic Approaches Involving Mitochondria in the Treatment of Acute Kidney Injury". Seminars in Nephrology 151676. doi : 10.1016/j.semnephrol.2025.151676 (inactive 18 November 2025). PMID 41027799 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li>^ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information . 30 (1). hdl : 10665/331046 .</li><li>^ "Stealth BioTherapeutics Announces FDA Accelerated Approval of Forzinity (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome" (Press release). Stealth Biotherapeutics. 19 September 2025 . Retrieved 20 September 2025 – via PR Newswire.</li><li># Further reading</li><li>Kloner RA, Shi J, Dai W (February 2015). "New therapies for reducing post-myocardial left ventricular remodeling" . Annals of Translational Medicine . 3 (2): 20. doi : 10.3978/j.issn.2305-5839.2015.01.13 (inactive 18 November 2025). PMC 4322169 . PMID 25738140 . {{ cite journal }} : CS1 maint: DOI inactive as of November 2025 ( link )</li><li># External links</li><li>"Elamipretide ( Code - C171874 )" . EVS Explore . Retrieved 20 September 2025 .</li><li>"Elamipretide Hydrochloride ( Code - C171875 )" . EVS Explore . Retrieved 20 September 2025 .</li><li>Medicine</li><li>Drugs not assigned an ATC code</li><li>Orphan drugs</li><li>Tetrapeptides</li><li>All articles with bare URLs for citations</li><li>Articles with bare URLs for citations from October 2025</li><li>Articles with PDF format bare URLs for citations</li><li>CS1 maint: DOI inactive as of November 2025</li><li>Source attribution</li><li>CS1:Vancouver names with accept markup</li><li>Articles with short description</li><li>Short description matches Wikidata</li><li>Use American English from September 2025</li><li>All Wikipedia articles written in American English</li><li>Use dmy dates from September 2025</li><li>Short description is different from Wikidata</li><li>Articles without EBI source</li><li>Multiple chemicals in Infobox drug</li><li>Chemicals using indexlabels</li><li>Chemical articles with multiple CAS registry numbers</li><li>Articles containing unverified chemical infoboxes</li><li>Citation overkill</li><li>Articles tagged with the inline citation overkill template from November 2025</li><li>This page was last edited on 10 December 2025, at 01:36 (UTC) .</li><li>Text is available under the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization.</li><li>Privacy policy</li><li>Disclaimers</li><li>Contact Wikipedia</li><li>Legal & safety contacts</li><li>Code of Conduct</li><li>Developers</li><li>Statistics</li><li>Cookie statement</li><li>Mobile view</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://pubchem.ncbi.nlm.nih.gov/compound/Elamipretide" rel="noopener noreferrer" target="_blank">https://pubchem.ncbi.nlm.nih.gov/compound/Elamipretide</a></p>
  <ul>
    <li># JavaScript is required...</li><li>Please enable Javascript in order to use PubChem website.</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://clinicaltrials.gov/search?cond=&term=Elamipretide" rel="noopener noreferrer" target="_blank">https://clinicaltrials.gov/search?cond=&term=Elamipretide</a></p>
  <ul>
    <li>Study record managers: refer to the Data Element Definitions if submitting registration or results information.</li><li>Search for terms</li>
  </ul>
</section>
            <p class="disclaimer-link"><small>Back to the main peptide list: <a href="../peptides.html">Peptides Overview</a>.</small></p>
          </main>
          <footer>
            © MinMaxMuscle. Discipline builds the body. Systems keep it.
          </footer>
          <script src="../assets/js/script.js"></script>
        </body>
        </html>